NEW YORK (TheStreet) -- RATINGS CHANGES
Baidu (BIDU) was downgraded at Jefferies to hold from buy. Twelve-month price target is $196. First-quarter revenue missed consensus by 1%, and second-quarter guidance was weaker than expected. Despite large recurring investments in O2O, Jefferies believes BIDU's lack of a strong payment tool limits its O2O monetization potential.
Chipotle (CMG) was upgraded to outperform at BMO Capital. Twelve-month price target is $760. Same-store sales should inflect soon and the company should see lower input costs, BMO Capital said.
Cash America International (CSH) was upgraded at JMP Securities to market outperform from market perform. Twelve-month price target is $32. JMP Securities said its analysts are increasingly comfortable in their belief that the business is best valued on an EBITDA and free-cash-flow basis, and the shares look very compelling in this regard.
Constant Contact (CTCT) was downgraded at Credit Suisse to neutral from outperform. Twelve-month price target is $30. Estimates were also cut, given the company's new guidance, Credit Suisse said.
Control4 (CTRL) was downgraded at Canaccord Genuity to hold from buy. Twelve-month price target is $13. After yet another reset in expectations, analysts are downgrading CTRL, Canaccord said. Although analysts love the product and believe the sector shows promise, they need to step to the sidelines until they can gain more confidence in sustainable growth, Canaccord also said.
Expedia (EXPE) was upgraded at RBC Capital to outperform. Twelve-month price target is $120. Company is seeing better growth and improving execution, RBC Capital said.
Federal Signal (FSS) was downgraded at Keybanc to sector weight from overweight. Valuation call, as the stock reached the previous 12-month price target of $17, Keybanc said.
GrafTech International (GTI) was downgraded at Jefferies to hold from buy. Twelve-month price target is $5.05. With electrode markets worse than expected, reduced long-term prospects for Seadrift/ES, and dilution from GTI's proposed stock offering, analysts no longer see sufficient fundamental near-term upside, Jefferies said.
Integra Lifesciences (IART) was upgraded at Wells Fargo to outperform from market perform. Company is growing faster and becoming more profitable, Wells Fargo said.
Kindred Healthcare (KND) was reinstated at Barclays with an overweight rating. Twelve-month price target is $36. Analysts view KND as uniquely positioned to take advantage of the broad growth opportunity within postacute services, Barclays said.